Key result
Epoprostenol is considered a safe and effective destination treatment for high-risk pulmonary arterial hypertension, though it remains underused in clinical practice.
Why the study?
Despite being the best treatment option for high-risk PAH patients, unsolved questions remain regarding epoprostenol dosing, combination therapy, and utility in specific PAH etiologies, leading to underuse in clinical practice.
Does epoprostenol improve outcomes in high-risk pulmonary arterial hypertension patients?
Does epoprostenol improve outcomes in high-risk pulmonary arterial hypertension patients?
Epoprostenol remains a crucial, albeit underutilized, destination therapy for high-risk pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Supports epoprostenol as destination therapy in high-risk PAH; leaves open barriers to adoption and need for prospective data.
: Epoprostenol is still the best treatment option for high-risk PAH patients. Nevertheless, there are many unsolved questions: drug dosing, its use in combination therapy with other pulmonary vasodilators, and the utility in PAH associated with connective tissue disease, congenital heart disease, or pulmonary veno-occlusive disease are only a few examples. Its safety and efficacy are supported by clinical trials, observational work, and experience, both as monotherapy and in combination therapy. Epoprostenol should be considered a destination treatment in high-risk patients and not only as a bridge to pulmonary transplantation. However, it remains underused in clinical practice.
No takes yet. Share an insight, caveat, or question.
Ropero et al. (2021) conducted a review in Pulmonary arterial hypertension. Epoprostenol was evaluated. Epoprostenol is considered a safe and effective destination treatment for high-risk pulmonary arterial hypertension, though it remains underused in clinical practice.
Synapse has enriched 10 related papers. Consider them for comparative context: